key: cord-0742391-jppqme33
authors: Olea, B.; Vicent, E. A.; Torres, I.; Amat, P.; Remigia, M. J.; Gozalbo, R.; Rodriguez, J.; Buesa, J.; Blasco, M. L.; Redon, J.; Signes, J.; Navarro, D.
title: Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
date: 2021-01-06
journal: nan
DOI: 10.1101/2021.01.05.20249027
sha: 5bdd7991c42ca236adefe2d9fe3b54bfd6c23db4
doc_id: 742391
cord_uid: jppqme33

Objectives: There is an imperative need to determine the durability of adaptive immunity to SARS-CoV-2. We enumerated SARS-CoV-2-reactive CD4+ and CD8+ T cells targeting S1 and M proteins and measured RBD-specific serum IgG over a period of 2-6 months after symptoms onset in a cohort of subjects who had recovered from severe clinical forms of COVID-19. Methods: We recruited 58 patients (38 males and 20 females; median age, 62.5 years), who had been hospitalized with bilateral pneumonia, 60% with one or more comorbidities. IgG antibodies binding to SARS-CoV-2 RBD were measured by ELISA. SARSCoV-2-reactive CD69+ -expressing-IFN{gamma}-producing-CD4+ and CD8+ T cells were enumerated in heparinized whole blood by flow cytometry for ICS. Results: Detectable SARS-CoV-2-S1/M-reactive CD69+ -IFN-{gamma} CD4+ and CD8+ T cells were displayed in 17 (29.3%) and 6 (10.3%) subjects respectively, at a median of 84 days after onset of symptoms (range, 58-191 days). Concurrent comorbidities increased the risk (OR, 3.15; 95% CI, 1.03-9.61; P=0.04) of undetectable T-cell responses in models adjusted for age, sex and hospitalization ward. Twenty-one out of the 35 patients (60%) had detectable RBD-specific serum IgGs at a median of 118 days (range, 60 to 145 days) after symptoms onset. SARS-CoV-2 RBD specific IgG serum levels were found to drop significantly over time. Conclusion: A relatively limited number of subjects who developed severe forms of COVID-19 had detectable SARS-CoV-2-S1/M IFN{gamma} CD4+ and CD8+ T cells at midterm after clinical diagnosis. Our data also indicated that serum levels of RBD specific IgGs decline over time, becoming undetectable in some patients.

specific IgGs decline over time, becoming undetectable in some patients. 48 49 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. lasting persistence (over years) [19, 20] , yet the durability of SARS-CoV-2 adaptive 65 immunity remains to be established. Determining whether SARS-CoV-2 B-and T-cell 66 responses persist over time following natural infection or after vaccination seems of 67 paramount relevance in designing effective public health policies to prevent virus 68 transmission and spread. In the current study we enumerated SARS-CoV-2-reactive 69 CD4 + and CD8 + T cells targeting S and M proteins, and measured IgG antibodies 70 binding to RBD of S protein, along a timeframe of up to 6 months after symptoms onset 71 in a cohort of recovered COVID-19 patients who had been hospitalized due to severe 72 clinical forms of the disease. 73 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. 

Serum specimens for quantitation of SARS-CoV-2 RBD-specific IgGs were available 146 from 35 patients, and collected at a median of 118 days (range, 60 to 145 days) from 147 onset of symptoms. Twenty-one of the 35 patients (60%) had detectable RBD-specific 148 IgGs (median, 1.8 AU/mL; range, 0.99-4.14 AU/mL). RBD-specific IgG reactivity 149 according to time of sampling (2-3 months vs. >3 months) is shown in Figure 1B Finally, we found no correlation between SARS-CoV-2 RBD-specific IgG levels and 163 SARS-CoV-2 CD4 + and CD8 + T-cell counts (P=0.12 and P=0.14, respectively) in 164 recovered COVID-19 patients. 165

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.05.20249027 doi: medRxiv preprint

The detection rate of SARS-CoV-2-reactive T cells (either CD4 + , CD8 + or both) was 168 comparable across patients admitted to ICU or other medical wards (P=0.82) ( Table 1) . 169

Likewise, both median SARS-CoV-2 CD4 + and CD8 + T-cell counts were similar 170 between groups (Figure 3 ). Neither age nor sex was found to influence either the 171 likelihood (Table 1) Table 1) . Both factors were found to increase the likelihood 181 of detecting an antibody response in multivariate models adjusted for age and 182 comorbidities (OR, 11.71; 95% CI, 1.86-73.7; P=0.009 and OR, 6.57; 95% CI, 1.04-183 41.4; P=0.04, respectively). Nevertheless, neither of these parameters had a significant 184 impact on serum SARS-CoV-2 IgG levels (not shown). 185

The net state of inflammation shortly after viral infections may shape the quality and 186 strength of ongoing adaptive immunity responses [24] . In this context, we next 187 compared serum peak levels of several inflammatory biomarkers, including IL-6, 188 ferritin and Dimer-D, measured within the first 15 days after hospitalization among 189 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. Here, we assessed SARS-CoV-2 T-and B-cell immune responses in patients who had 211 recovered from severe COVID-19 at medium term (from 2 to 6 months) after disease 212 presentation. We used a whole blood flow cytometry ICS method for detection and 213 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. Like other SARS-CoV-2 T-cell immunoassays [11, 12, 14, 15] , our ICS assay appears 219 capable of quantifying coronavirus cross-reactive T cells, as two out of seven non-220 exposed individuals exhibited detectable responses (not shown). 221

Likewise, RBD-specific IgG levels strongly correlate with NtAb titers as measured 222 using live or S-pseudotyped SARS-CoV-2, so they can be used as a proxy for inferring 223 the neutralizing activity of sera [6,7,23]. 224

Several major findings arose from our study. First, SARS-CoV-2-S1/M-reactive-IFN-γ 225 CD4 + and CD8 + T cells were detected in a limited number of recovered patients from 226 severe COVID-19 (around 30% and 10% for CD4 + and CD8 + T cells, respectively). 227 Furthermore, we were unable to document SARS-CoV-2 T-cell reactivity beyond day 228 130 after COVID-19 diagnosis. This latter observation must be interpreted with caution 229 given the low number of patients (n=3) tested within that timeframe. In a previous study 230 also recruiting severe COVID-19 patients [21], we reported that around 40% of patients 231 were capable of mounting SARS-CoV-2-S1/M-reactive IFN-γ-producing CD8 + T cell 232 responses shortly after infection (median, 27 days after symptoms onset); in that study, 233 SARS-CoV-2-reactive CD4 + T cell responses were not assessed. Nevertheless, other 234 studies including hospitalized COVID-19 patients [11, 12] found detectable functional 235

CD4 + T-cell responses to both S1 and M proteins in a large fraction of patients either 236 during the acute phase of the disease or at short-term convalescence. Taken collectively, 237 the above observations suggest that functional SARS-CoV-2-S1/M-reactive T-cell 238 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. The current study has several limitations that must be acknowledged; predominantly, 282 the reduced cohort size. Second, T-cell immunity analyses were conducted at a single 283 time point. We cannot rule out that detectability of the two SARS-CoV-2-reactive T 284 cells by the immunoassay used herein may fluctuate over time. Moreover, no whole 285 blood specimens drawn at the time of patient hospitalization were available for T-cell 286 immunity assessment. Third, T cells and antibodies targeting other antigen specificities, 287 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.05.20249027 doi: medRxiv preprint 13 which may afford protection against SARS-CoV-2, were not evaluated. Fourth, T-cell 288 functionalities other than IFN-γ production upon antigenic stimulation were not 289 explored. Fifth, we cannot be certain whether our whole blood T-cell immunoassay 290 might be less sensitive than others using fresh or cryopreserved isolated PBMCs. Sixth, 291 taking serum peak levels of IL-6, Dimer-D and ferritin during the first 15 days after 292 symptoms onset is an admittedly arbitrary time point for analyses which may not have 293 captured the true net state of systemic inflammation generated shortly after SARS-CoV-294 2 infection. 295

In summary, we have shown that a relatively low number of subjects who developed 296 severe forms of COVID-19 had detectable SARS-CoV-2-S1/M IFNγ CD4 + and CD8 + T 297 cells at medium term after clinical diagnosis (up to 6 months), particularly those with 298 concurrent comorbidities. Our data also indicated that serum levels of RBD-specific 299 IgGs decline over time, becoming undetectable in some patients. Elucidating whether 300 individuals lacking these specific adaptive immune responses are susceptible to 301 reinfection is beyond the scope of the current study and needs to be addressed in future 302 research. 303

We thank all personnel working at Clinic University Hospital for their unwavering 305 commitment in the fight against COVID-19. 306

This work received no public or private funds. 308

The authors declare no conflicts of interest. 310 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.05.20249027 doi: medRxiv preprint

Response During SARS-CoV-2 Infection: Lessons From the Past

Dissecting antibody-mediated protection against SARS-CoV-2

CoV-2 Infection

CoV: Implications for vaccine development against MERS-CoV

SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal 328 model

The receptor binding domain of the viral spike protein is an immunodominant and 331 highly specific target of antibodies in SARS-CoV-2 patients

Selective and 359 cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

T cell responses in patients with COVID-19

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild 364 COVID-19

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Memory T cell 369 responses targeting the SARS coronavirus persist up to 11 years post-infection

SARS-CoV-2 T cell immunity: specificity, function, 372 durability, and role in protection

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of 379 hospitalized COVID-19 patients

The immune battlefield: The impact of inflammatory 381 cytokines on CD8+ T-cell immunity

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and 342 associations with age and disease severity. Cell 2020;183:1-17. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.05.20249027 doi: medRxiv preprint